Y
Yoshikazu Inoue
Researcher at Cincinnati Children's Hospital Medical Center
Publications - 273
Citations - 17662
Yoshikazu Inoue is an academic researcher from Cincinnati Children's Hospital Medical Center. The author has contributed to research in topics: Idiopathic pulmonary fibrosis & Medicine. The author has an hindex of 48, co-authored 233 publications receiving 12648 citations. Previous affiliations of Yoshikazu Inoue include Niigata University.
Papers
More filters
Journal Article
Application of interlocking detachable coil (IDC) in superselective bronchial artery embolization
Hideo Ishikawa,Takeshi Kimura,Akiko Oya,Atsushi Kamitani,Yoshikazu Inoue,Katsuhiro Suzuki,Masanori Akira,Seiji Hayashi,Masaaki Kawahara,Zenji Okada,Kentaro Kimura,Keiji Iuchi,Mitsunori Sakatani +12 more
TL;DR: This is the first-ever report documenting the usefulness of IDC for BAE, a mechanically detachable coil allowing the operator to seek the ideal shape until its final release, which is significantly shorter than in the non-IDC group.
Journal Article
[Multidisciplinary assessment of effects, safety and procedure of whole lung lavage for 8 patients with autoimmune pulmonary alveolar proteinosis].
Chikatoshi Sugimoto,Toru Arai,Akihide Nishiyama,Yoshikazu Inoue,Tomoko Kagawa,Masanori Akira,Akiko Matsumuro,Masaki Hirose,M Kitaichi,Seiji Hayashi +9 more
TL;DR: It is concluded that WLL is an effective and safe method for the treatment of APAP, and all parameters except for anti GM-CSF antibody are useful to evaluate the effect of WLL.
Journal ArticleDOI
Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial.
Yoshikazu Inoue,Takafumi Suda,Hideya Kitamura,Masaki Okamoto,Arata Azuma,Naohiko Inase,Masataka Kuwana,Shigeki Makino,Yasuhiko Nishioka,Takashi Ogura,Ayako Takizawa,Hiroyuki Ugai,Susanne Stowasser,Rozsa Schlenker-Herceg,Tsutomu Takeuchi +14 more
TL;DR: In this paper, the authors evaluated the efficacy and safety of nintedanib in the Japanese population in a randomized, double-blind, placebo-controlled INBUILD trial.
Journal Article
Effect of baseline FVC on decline in lung function with nintedanib: Results from the INPULSIS™ trials
Ulrich Costabel,Yoshikazu Inoue,Luca Richeldi,Harold R. Collard,Susanne Stowasser,I. Tschoepe,Arata Azuma +6 more
TL;DR: A subgroup analysis of pooled data from the INPULSIS™ trials showed that nintedanib 150 mg twice daily slowed the decline in lung function in patients with IPF, independent of severity of lung function impairment at baseline.
Journal ArticleDOI
Autoimmune Pulmonary Alveolar Proteinosis Following Pulmonary Aspergillosis.
TL;DR: Aspergillus infection may be associated with the onset and progression of APAP and tolerance to GM-CSF therapy and the patient ultimately died of respiratory failure caused by APAP four months after General CSF therapy commenced.